Phaseline

Companies › Algernon Pharmaceuticals

Algernon Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 2; Neurology, Psychiatry.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
N,N-Dimethyltryptamine (DMT)
Serotonin receptor agonist
–Phase 1Stroke; MDD–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05559931N,N-Dimethyltryptamine (DMT)Phase 1StrokeNeurologyMar 2026
NCT07562191N,N-Dimethyltryptamine (DMT)Phase 2MDDPsychiatryFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.